An Open Label Feasibility Trial Investigating FE 202158 as Potential Primary Vasopressor Treatment in Patients With Vasodilatory Hypotension in Early Septic Shock.
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2017
Price : $35 *
At a glance
- Drugs Selepressin (Primary)
- Indications Hypotension; Septic shock
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 22 Apr 2014 New source identified and integrated; European Clinical Trials Database record.
- 10 Apr 2014 New trial record